{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:52:51Z","timestamp":1764132771637},"reference-count":146,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.iccl.2013.05.008","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T04:34:21Z","timestamp":1373344461000},"page":"643-663","source":"Crossref","is-referenced-by-count":3,"title":["Monitoring and Reversal of Anticoagulation and Antiplatelets"],"prefix":"10.1016","volume":"2","author":[{"given":"Gregory W.","family":"Yost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Steinhubl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iccl.2013.05.008_bib1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings\/clinical perspective","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.CIR.95.2.438","article-title":"Stent endothelialization","volume":"95","author":"Van Belle","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2008.02.091","article-title":"Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation","volume":"102","author":"Xie","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib4","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1161\/CIR.0b013e31823ba622","article-title":"ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib5","doi-asserted-by":"crossref","first-page":"728S","DOI":"10.1378\/chest.114.5_Supplement.728S","article-title":"Antithrombotic therapy in patients undergoing coronary angioplasty","volume":"114","author":"Popma","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.iccl.2013.05.008_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","article-title":"Transluminal dilatation of coronary-artery stenosis","volume":"1","author":"Gruntzig","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib7","first-page":"1721","article-title":"Percutaneous\u00a0transluminal dilatation of chronic coronary stenoses. First experiences","volume":"108","author":"Gruntzig","year":"1978","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.iccl.2013.05.008_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A\u00a0randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease","volume":"331","author":"Fischman","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A\u00a0comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"331","author":"Serruys","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00001573-200109000-00007","article-title":"Adjunctive pharmacotherapy for coronary stenting","volume":"16","author":"Harding","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib11","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","article-title":"Predictors of bleeding and time dependence of association of bleeding with mortality\/clinical perspective","volume":"123","author":"Hochholzer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478","article-title":"Anticoagulant therapy for percutaneous coronary intervention","volume":"3","author":"Rao","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/ica.10.46","article-title":"Anticoagulation in percutaneous coronary intervention","volume":"2","author":"O'Neill","year":"2010","journal-title":"Intervent Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ccd.21204","article-title":"Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention","volume":"70","author":"Garg","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib15","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS Trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(87)90291-1","article-title":"Effectiveness of low-dose heparin in prevention of myocardial reinfarction","volume":"1","author":"Neri Serneri","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ahj.2009.12.041","article-title":"Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents","volume":"159","author":"Li","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0735-1097(00)00695-1","article-title":"Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina","volume":"36","author":"Montalescot","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.CIR.83.3.927","article-title":"Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up","volume":"83","author":"de Feyter","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2013.05.008_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.1973.tb01662.x","article-title":"Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex","volume":"24","author":"Marciniak","year":"1973","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iccl.2013.05.008_bib24","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.iccl.2013.05.008_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/ajcp\/94.3.297","article-title":"Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT","volume":"94","author":"D'Angelo","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.iccl.2013.05.008_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0002-8703(92)90793-U","article-title":"The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty","volume":"123","author":"McGarry","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty","volume":"23","author":"Ferguson","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/01.CIR.93.4.667","article-title":"Relation between activated clotting time during angioplasty and abrupt closure","volume":"93","author":"Narins","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial","volume":"29","author":"Montalescot","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ccd.20355","article-title":"Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory","volume":"65","author":"Doherty","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib34","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib35","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","article-title":"Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs","author":"Weitz","year":"2011"},{"key":"10.1016\/j.iccl.2013.05.008_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0039-6060(96)80157-7","article-title":"Effects of differing rates of protamine reversal of heparin anticoagulation","volume":"119","author":"Wakefield","year":"1996","journal-title":"Surgery"},{"key":"10.1016\/j.iccl.2013.05.008_bib37","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.iccl.2013.05.008_bib38","first-page":"12","article-title":"Pharmacology of low molecular weight heparins","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.iccl.2013.05.008_bib39","first-page":"72","article-title":"Low-molecular-weight heparins in the cardiac catheterization laboratory","volume":"31","author":"Kadakia","year":"2004","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.iccl.2013.05.008_bib40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0733-8627(05)70233-9","article-title":"Pharmacology of low molecular weight heparins","volume":"19","author":"Kleinschmidt","year":"2001","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.iccl.2013.05.008_bib41","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/01.CIR.103.18.2310","article-title":"The search for replacements for unfractionated heparin","volume":"103","author":"Antman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","article-title":"Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia","volume":"26","author":"Gurfinkel","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A\u00a0comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib47","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1016\/S0002-8703(98)70265-0","volume":"135","author":"Antman","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib48","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.292.1.45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"SYNERGY Trial Investigators","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2009.05.022","article-title":"Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study","volume":"158","author":"Drouet","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib51","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib52","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J\u00a0Invasive Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(02)02631-1","article-title":"Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the coronary revascularization using integrilin and single bolus enoxaparin study","volume":"41","author":"Bhatt","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib54","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/archinte.167.22.2423","article-title":"Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials","volume":"167","author":"Dumaine","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ccd.21764","article-title":"Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial","volume":"73","author":"Gallo","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib56","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1067\/mhj.2001.117317","article-title":"Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?","volume":"142","author":"Henry","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0049-3848(02)00340-7","article-title":"In\u00a0vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation","volume":"107","author":"Linkins","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.iccl.2013.05.008_bib58","doi-asserted-by":"crossref","first-page":"33L","DOI":"10.1016\/S0002-9149(98)00111-8","article-title":"Monitoring of low-molecular-weight heparins in cardiovascular disease","volume":"82","author":"Abbate","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib59","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","article-title":"A\u00a0unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention","volume":"40","author":"Choussat","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib61","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","article-title":"Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin","volume":"110","author":"Montalescot","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ccd.10726","article-title":"Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study","volume":"61","author":"Martin","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.poc.0000157177.83327.3f","article-title":"Point-of-care monitoring of enoxaparin in the presence of GpIIb\/IIIa combined therapy during percutaneous coronary interventions","volume":"4","author":"Rouby","year":"2005","journal-title":"Point Care"},{"key":"10.1016\/j.iccl.2013.05.008_bib64","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1067\/mhj.2000.111608","article-title":"Applications of monitoring platelet glycoprotein IIb\/IIIa antagonism and low molecular weight heparins in cardiovascular medicine","volume":"140","author":"Moliterno","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0735-1097(03)01053-2","article-title":"A\u00a0novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study","volume":"42","author":"Moliterno","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib67","doi-asserted-by":"crossref","first-page":"576S","DOI":"10.1378\/chest.126.3_suppl.576S","article-title":"Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Popma","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.iccl.2013.05.008_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-3848(87)90343-4","article-title":"Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors","volume":"48","author":"Lindblad","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.iccl.2013.05.008_bib69","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2013.05.008_bib70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0037-1614445","article-title":"Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent\u2013a pilot study in the setting of coronary angioplasty","volume":"81","author":"Vuillemenot","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2013.05.008_bib71","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A\u00a0synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib72","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A\u00a0dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study","volume":"43","author":"Simoons","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib73","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib74","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.CIR.0000158485.70761.67","article-title":"Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial","volume":"111","author":"Mehta","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib75","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib76","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib77","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib78","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","article-title":"Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty","volume":"87","author":"Topol","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib79","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib80","first-page":"27F","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates","year":"2000","journal-title":"J\u00a0Invasive Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib81","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00129784-200707040-00003","article-title":"Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine","volume":"7","author":"Wong","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.iccl.2013.05.008_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/14779072.5.1.57","article-title":"Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia","volume":"5","author":"Lewis","year":"2007","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.iccl.2013.05.008_bib83","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.iccl.2013.05.008_bib84","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib85","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","article-title":"Clinical outcomes of bivalirudin for ischemic heart disease","volume":"100","author":"Kong","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib86","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib87","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib88","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non\u2013ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib89","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib90","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2165\/00003495-200565130-00010","article-title":"Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention","volume":"65","author":"Moen","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.iccl.2013.05.008_bib91","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2010.02.044","article-title":"Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study","volume":"148","author":"Rossig","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib92","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0091270010372627","article-title":"Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters","volume":"51","author":"Akimoto","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.iccl.2013.05.008_bib93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/14796678.4.1.33","article-title":"Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence","volume":"4","author":"van Werkum","year":"2008","journal-title":"Future Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib94","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib95","doi-asserted-by":"crossref","first-page":"776S","DOI":"10.1378\/chest.08-0685","article-title":"The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Becker","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.iccl.2013.05.008_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.iccl.2013.05.008_bib97","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/14750708.2.3.465","article-title":"Platelets and new antiplatelet drugs","volume":"2","author":"Reiter","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.iccl.2013.05.008_bib98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2009.03.044","article-title":"Combining antiplatelet and anticoagulant therapies","volume":"54","author":"Holmes","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib99","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","article-title":"Aspirin dose for the prevention of cardiovascular disease: a systematic review","volume":"297","author":"Campbell","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib100","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib101","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2174\/138945011797635858","article-title":"Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent","volume":"12","author":"Steinhubl","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.iccl.2013.05.008_bib102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/POC.0b013e31820f852e","article-title":"Comparison of a point-of-care platelet function testing to light transmission aggregometry in patients undergoing percutaneous coronary intervention pretreated with aspirin and clopidogrel","volume":"10","author":"Polena","year":"2011","journal-title":"Point Care"},{"key":"10.1016\/j.iccl.2013.05.008_bib103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2174\/1871529X11006030224","article-title":"New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine","volume":"10","author":"Hezard","year":"2010","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.iccl.2013.05.008_bib104","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib105","first-page":"527","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib106","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2005.10.047","article-title":"Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention","volume":"47","author":"Steinhubl","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib107","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib108","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib109","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/HCO.0b013e328339f1aa","article-title":"Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents","volume":"25","author":"Wong","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib110","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib111","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib112","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.iccl.2013.05.008_bib113","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib114","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0032-1301417","article-title":"High platelet reactivity and antiplatelet therapy resistance","volume":"38","author":"Linden","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.iccl.2013.05.008_bib116","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ahj.2009.02.012","article-title":"Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial","volume":"157","author":"Price","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib117","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcin.2012.02.002","article-title":"The illusion of \u201coptimal\u201d platelet inhibition","volume":"5","author":"Steinhubl","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib118","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1053\/hj.1999.v138.99077","article-title":"Platelet glycoprotein IIb\/IIIa antagonists in percutaneous coronary revascularization","volume":"138","author":"Dangas","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9149(03)00816-6","article-title":"Meta-analysis of survival with platelet glycoprotein IIb\/IIIa antagonists for percutaneous coronary interventions","volume":"92","author":"Kong","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation","volume":"330","author":"The EPIC Investigators","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib121","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","author":"The EPILOG Investigators","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib122","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to\u00a0assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"352","author":"The EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib123","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00005344-200403000-00001","article-title":"Glycoprotein IIb-IIIa\u00a0antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part\u00a01: the evidence of benefit","volume":"43","author":"Zimarino","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.iccl.2013.05.008_bib124","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00129784-200303060-00005","article-title":"Glycoprotein IIb\/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention","volume":"3","author":"Nguyen","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.iccl.2013.05.008_bib125","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1093\/eurheartj\/ehi620","article-title":"Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study","volume":"26","author":"The ADMIRAL Investigators","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib126","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib127","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","article-title":"A\u00a0randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction","volume":"42","author":"Antoniucci","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib128","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"The GUSTO IV-ACS Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib129","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 Randomized Trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2013.05.008_bib130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/ica.10.33","article-title":"Glycoprotein IIb\/IIIa inhibitors during percutaneous coronary interventions","volume":"2","author":"Koutouzis","year":"2010","journal-title":"Intervent Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib131","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","author":"The IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib132","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib133","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"The ESPRIT Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2013.05.008_bib134","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"The RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib135","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib136","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.008_bib137","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.008_bib138","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00000542-200205000-00029","article-title":"Platelet glycoprotein IIb\/IIIa antagonists: pharmacology and clinical developments","volume":"96","author":"Warltier","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.iccl.2013.05.008_bib139","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.97.1.5","article-title":"Monitoring platelet GP IIb\/IIIa antagonist therapy","volume":"97","author":"Coller","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib140","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1067\/mhj.2002.121734","article-title":"The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy","volume":"143","author":"Wheeler","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib141","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib142","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0002-9149(02)02362-7","article-title":"Relation of platelet inactivation with intravenous glycoprotein IIb\/IIIa antagonists to major bleeding (from the GOLD study)","volume":"89","author":"Tamberella","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.008_bib143","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.008_bib144","doi-asserted-by":"crossref","first-page":"s38","DOI":"10.1067\/mhj.2000.103742","article-title":"Clinical challenges of platelet glycoprotein IIb\/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment","volume":"139","author":"Tcheng","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2013.05.008_bib145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11886-003-0068-2","article-title":"Emergency management of hemorrhagic complications in the era of glycoprotein IIb\/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents","volume":"5","author":"Schroeder","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.iccl.2013.05.008_bib146","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ccd.10576","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis","volume":"59","author":"Sperling","year":"2003","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745813000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745813000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:41:04Z","timestamp":1645994464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745813000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S2211745813000497"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2013.05.008","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}